Medicare Is Expanding TMS Coverage — But the Eligibility Criteria Still Block the Patients Who Need It Most

Transcranial magnetic stimulation has been FDA-cleared for treatment-resistant depression since 2008 (NeuroStar, Neuronetics). Deep TMS received clearance in 2013 (BrainsWay). Accelerated TMS protocols received FDA clearance in 2022 (Stanford Neuromodulation Therapy / SAINT). The evidence base for TMS in TRD is substantial: multiple meta-analyses consistently show response rates of 50–60% and remission rates of 30–35% in patients who have failed 1–4 antidepressant trials.

Despite 16+ years of FDA clearance, TMS access remains severely constrained by payer criteria that have not kept pace with clinical evidence. CMS updated its Medicare coverage determination for TMS in 2024, and the changes are clinically significant — but eligibility requirements still exclude the patients with the highest disease burden.

What Changed in CMS Coverage

Prior to 2024: Medicare TMS coverage required:

• Diagnosis of MDD (unipolar only)
• Failure of ≥4 antidepressant trials in the current episode
• Documentation of medication intolerance or contraindication in some circumstances
• Deep TMS was not covered under the original NCD

2024 CMS updates:

• Reduced failed trial requirement: Many contractors now recognize coverage with ≥3 failed adequate trials (down from 4), more closely aligned with how TRD is defined in clinical literature
• Deep TMS coverage expanded: BrainsWay dTMS is now covered by more regional contractors; FDA clearance for OCD and MDD with anxious distress now reflected in some coverage policies
• Accelerated TMS protocols (SAINT): Under review; some Advantage plans covering via prior authorization; traditional Medicare coverage still limited
• MDD with comorbid anxiety: Some plans now explicitly covering TMS for MDD with anxious distress subtype, which had previously been a denial basis

What Still Blocks Access

The clinical problem with current coverage criteria — even after the 2024 updates — is a structural mismatch between how payers define treatment failure and how TRD is actually understood clinically.

The "adequate trial" documentation problem: Coverage requires documented adequate trials (minimum effective dose × minimum 6 weeks). In practice, many patients have multiple informal trials — shorter courses, subtherapeutic doses, discontinued early due to side effects — that do not meet the "adequate" threshold even though they represent genuine clinical experience with antidepressants. Clinicians who did not document adequately or patients who can't recall trial details may be unable to establish coverage eligibility despite long treatment histories.

Bipolar depression exclusion: Traditional Medicare TMS coverage is limited to unipolar MDD. Bipolar depression — which constitutes a substantial proportion of TRD presentations — remains off-label for TMS despite accumulating evidence (particularly for the depressive phase of bipolar II, where antidepressant risk of switching to hypomania makes stimulation-based alternatives particularly rational).

Chronic low-grade depression (dysthymia/PDD): Persistent depressive disorder (PDD), which is often poorly responsive to antidepressants and has been treated with TMS off-label with some success, is typically not covered.

SAINT/accelerated TMS: The Stanford accelerated neuromodulation therapy protocol (5 sessions/day × 5 days = 1-week intensive) showed 78.6% remission in an RCT (Cole et al. 2022) — a result that, if replicated at scale, would be transformative. Traditional Medicare does not yet cover this protocol. Some Medicare Advantage plans cover it via prior auth, but inconsistently.

Practical Implications for Therapists

TMS is increasingly discussed by patients, particularly those who have learned about it through social media or after reading about SAINT. Clinicians need to be able to provide accurate information:

What TMS is: A non-invasive outpatient procedure (30–40 min/session for standard TMS; 3 min for TBS protocols), administered 5 days/week for 4–6 weeks. No anesthesia, no seizure induction, no significant cognitive impairment. Standard side effect is headache at stimulation site; typically mild.

What TMS is not: It is not ECT. The mechanism (focused magnetic field inducing electrical changes in specific cortical areas) is entirely different from ECT (generalized seizure). The side effect profile is not comparable. Patients conflating the two can be redirected.

Coverage navigation: For patients interested in TMS:

1. Confirm diagnosis is unipolar MDD (not bipolar)
2. Help patient reconstruct treatment history with adequate trial documentation
3. Consider whether current insurance plan has a specific TMS prior authorization pathway
4. Note that some TMS practices work directly with insurers on prior auth; others require prescriber-driven documentation